Clinical Data to Discuss MicroArray Quality Control (MAQC) Project Results at Discovery-2-Diagnostics Conference.

NEWTON, Mass. -- FDA Scientist Keynote Panel Presentation on MAQC Project Results from Initiative Assessing Reproducibility of Microarray Data

Clinical Data Inc. (NASDAQ: CLDA), a worldwide leader in providing comprehensive molecular biology and pharmacogenomics services as well as clinical diagnostics to improve patient care, announced today that its Cogenics division will discuss its integral role in the MicroArray Quality Control (MAQC) project for generating and analyzing multi-platform gene expression data at Booth # 312 at the Discovery-2-Diagnostics (D2D) Conference & Exhibition to be held from September 25-27 at the Hynes Convention Center in Boston, Mass.

At the conference, Leming Shi, Ph.D., National Center for Toxicological Research, FDA, is expected to present the results of the newly released MAQC project during a keynote panel presentation on Monday, September 25 at 4:00 PM ET.

Researchers at Cogenics are authors on three of the six publications reporting the Phase I results of the MAQC program in the September 2006 issue of Nature Biotechnology. Cogenics supports the release of these data as a key step to establishing the use of microarrays in the discovery, development and review of FDA-regulated products.

Robert Bondaryk, Ph.D., General Manager and Unit Head, Cogenics, said, "As a result of this major initiative, we now have a framework for assessing the potential for clinical and regulatory use of the gene expression data derived from various microarray platforms, Cogenics is pleased to have contributed to this community-wide effort in objectively examining the cross-platform compatibility, within-platform precision, and inter-laboratory reproducibility of microarray technologies. We look forward to discussing this groundbreaking project with members of the life science community at the Discovery-2-Diagnostics Conference & Exhibition, and thereafter to participating in the Phase II portion of the MAQC program."

Clinical Data Co-Authored Publications Available from Nature Biotechnology

www.nature.com/nbt/focus/maqc/index.html

--The MicroArray Quality Control (MAQC) project shows interplatform reproducibility of gene expression measurements.

--Rat toxicogenomic study reveals analytical consistency across microarray platforms

--Performance comparison of one-color and two-color platforms within the Microarray Quality Control (MAQC) project

About Clinical Data, Inc.

Clinical Data, Inc., a worldwide leader in providing comprehensive molecular biology and pharmacogenomics services and genetic tests to improve patient care, is organized under three worldwide divisions: Cogenics(TM); PGxHealth(TM) ; and Vital Diagnostics(TM) . The Pharmacogenomics and Molecular Services(TM) division, Cogenics, consolidates operations of Genaissance Pharmaceuticals, Inc., Lark Technologies, Inc. , Icoria, Inc., and Genome Express SA. Cogenics provides a comprehensive range of molecular biology and pharmacogenomics services to pharmaceutical, biotech, academic, agricultural, and government clients. These services are offered in both research and regulated environments and have applications across the lifecycle of pharmaceutical product development including pharmacovigilance requirements post-launch. PGxHealth builds upon existing assets and know-how acquired from Genaissance Pharmaceuticals, Icoria, and Genome Express in the areas of genomics-based, genetic tests and therapeutic efficacy and safety biomarker development for drug utilization. PGxHealth develops, validates and commercializes novel Therapeutic Diagnostics(TM), in some instances in combination with new and existing therapeutics, to improve patient care. In addition, PGxHealth has a therapeutic drug candidate, vilazodone, currently in late stage clinical trials for the treatment of depression. The Vital Diagnostics division serves the clinical laboratory in the traditional in-vitro diagnostics market worldwide with a focus on the physician's office, hospital and small-to-medium sized laboratory segments. With customers in approximately 100 countries, Vital Diagnostics has achieved a leading market share for instruments and reagents sold into moderately complex physicians' office laboratories within the United States. Clinical Data currently employs a staff of approximately 425. The Company is headquartered in Newton, Massachusetts with operations in Texas, Connecticut, North Carolina, Rhode Island, and California as well as internationally in the UK, France, the Netherlands, Italy and Australia.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This press release contains certain forward-looking information and statements that are intended to be covered by the safe harbor for forward looking statements provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)", "feel(s)", "believe(s)", "will", "may", "anticipate(s)" and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements about our ability to successfully integrate the operations, business, technology and intellectual property obtained in our recent acquisitions; our ability to obtain regulatory approval for, and successfully introduce our new products; our ability to expand our long-term business opportunities; our ability to maintain normal terms with our customers and partners; financial projections and estimates and their underlying assumptions; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, the effects of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include, but are not limited to, whether Clinical Data will be able to develop or acquire additional products and attract new business and strategic partners; competition from pharmaceutical, biotechnology and diagnostics companies; the strength of our intellectual property rights; the effect on the Company's operations and results of significant acquisitions or divestitures made by major competitors; the Company's ability to achieve expected synergies and operating efficiencies in all of its acquisitions, and to successfully integrate its operations; and those risks discussed and identified by Clinical Data in its public filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. Clinical Data does not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Readers are also urged to carefully review and consider the various disclosures in Clinical Data's SEC reports, including but not limited to its Annual Report on Form 10-K for the fiscal year ended March 31, 2006, and fiscal 2005, 2006, and 2007 quarterly reports on Forms 10-QSB and 10-Q.

Internet Website: www.clda.com